1
|
Han B, Poppinga WJ, Zuo H, Zuidhof AB, Bos IST, Smit M, Vogelaar P, Krenning G, Henning RH, Maarsingh H, Halayko AJ, van Vliet B, Stienstra S, Graaf ACVD, Meurs H, Schmidt M. The novel compound Sul-121 inhibits airway inflammation and hyperresponsiveness in experimental models of chronic obstructive pulmonary disease. Sci Rep 2016; 6:26928. [PMID: 27229886 PMCID: PMC4882609 DOI: 10.1038/srep26928] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/14/2015] [Accepted: 05/11/2016] [Indexed: 12/15/2022] Open
Abstract
COPD is characterized by persistent airflow limitation, neutrophilia and oxidative stress from endogenous and exogenous insults. Current COPD therapy involving anticholinergics, β2-adrenoceptor agonists and/or corticosteroids, do not specifically target oxidative stress, nor do they reduce chronic pulmonary inflammation and disease progression in all patients. Here, we explore the effects of Sul-121, a novel compound with anti-oxidative capacity, on hyperresponsiveness (AHR) and inflammation in experimental models of COPD. Using a guinea pig model of lipopolysaccharide (LPS)-induced neutrophilia, we demonstrated that Sul-121 inhalation dose-dependently prevented LPS-induced airway neutrophilia (up to ~60%) and AHR (up to ~90%). Non-cartilaginous airways neutrophilia was inversely correlated with blood H2S, and LPS-induced attenuation of blood H2S (~60%) was prevented by Sul-121. Concomitantly, Sul-121 prevented LPS-induced production of the oxidative stress marker, malondialdehyde by ~80%. In immortalized human airway smooth muscle (ASM) cells, Sul-121 dose-dependently prevented cigarette smoke extract-induced IL-8 release parallel with inhibition of nuclear translocation of the NF-κB subunit, p65 (each ~90%). Sul-121 also diminished cellular reactive oxygen species production in ASM cells, and inhibited nuclear translocation of the anti-oxidative response regulator, Nrf2. Our data show that Sul-121 effectively inhibits airway inflammation and AHR in experimental COPD models, prospectively through inhibition of oxidative stress.
Collapse
MESH Headings
- Animals
- Anti-Inflammatory Agents, Non-Steroidal/pharmacology
- Antioxidants/pharmacology
- Cell Line, Transformed
- Chromans/chemistry
- Chromans/pharmacology
- Complex Mixtures/antagonists & inhibitors
- Complex Mixtures/pharmacology
- Disease Models, Animal
- Gene Expression Regulation
- Guinea Pigs
- Humans
- Hydrogen Sulfide/agonists
- Hydrogen Sulfide/blood
- Hypersensitivity/etiology
- Hypersensitivity/immunology
- Hypersensitivity/metabolism
- Hypersensitivity/prevention & control
- Inflammation
- Interleukin-8/antagonists & inhibitors
- Interleukin-8/genetics
- Interleukin-8/immunology
- Lipopolysaccharides/administration & dosage
- Lung
- Male
- Malondialdehyde/antagonists & inhibitors
- Malondialdehyde/metabolism
- Myocytes, Smooth Muscle/drug effects
- Myocytes, Smooth Muscle/immunology
- Myocytes, Smooth Muscle/pathology
- NF-E2-Related Factor 2/antagonists & inhibitors
- NF-E2-Related Factor 2/genetics
- NF-E2-Related Factor 2/immunology
- Neutrophils/drug effects
- Neutrophils/immunology
- Neutrophils/pathology
- Oxidative Stress
- Piperazines/chemistry
- Piperazines/pharmacology
- Pulmonary Disease, Chronic Obstructive/drug therapy
- Pulmonary Disease, Chronic Obstructive/immunology
- Pulmonary Disease, Chronic Obstructive/metabolism
- Pulmonary Disease, Chronic Obstructive/physiopathology
- Reactive Oxygen Species/antagonists & inhibitors
- Reactive Oxygen Species/metabolism
- Tars/chemistry
- Tars/toxicity
- Transcription Factor RelA/antagonists & inhibitors
- Transcription Factor RelA/genetics
- Transcription Factor RelA/immunology
Collapse
Affiliation(s)
- Bing Han
- University of Groningen, Department of Molecular Pharmacology, Groningen, the Netherlands
- GRIAC research institute, University of Groningen, University Medical Center Groningen, the Netherlands
| | - Wilfred J. Poppinga
- University of Groningen, Department of Molecular Pharmacology, Groningen, the Netherlands
- GRIAC research institute, University of Groningen, University Medical Center Groningen, the Netherlands
| | - Haoxiao Zuo
- University of Groningen, Department of Molecular Pharmacology, Groningen, the Netherlands
- GRIAC research institute, University of Groningen, University Medical Center Groningen, the Netherlands
| | - Annet B. Zuidhof
- University of Groningen, Department of Molecular Pharmacology, Groningen, the Netherlands
| | - I. Sophie T. Bos
- University of Groningen, Department of Molecular Pharmacology, Groningen, the Netherlands
| | - Marieke Smit
- University of Groningen, Department of Molecular Pharmacology, Groningen, the Netherlands
| | | | - Guido Krenning
- University of Groningen, University Medical Center Groningen, Dept. Pathology and Medical Biology, Laboratory for Cardiovascular Regenerative Medicine, Groningen, the Netherlands
| | - Robert H. Henning
- University of Groningen, Department of Clinical Pharmacy and Pharmacology, Groningen, the Netherlands
| | - Harm Maarsingh
- Palm Beach Atlantic University, Lloyd L. Gregory School of Pharmacy, Department of Pharmaceutical Sciences, West Palm Beach, FL, USA
| | - Andrew J. Halayko
- Department of Physiology and Pathophysiology, University of Manitoba, Winnipeg, Manitoba, Canada
| | | | | | | | - Herman Meurs
- University of Groningen, Department of Molecular Pharmacology, Groningen, the Netherlands
- GRIAC research institute, University of Groningen, University Medical Center Groningen, the Netherlands
| | - Martina Schmidt
- University of Groningen, Department of Molecular Pharmacology, Groningen, the Netherlands
- GRIAC research institute, University of Groningen, University Medical Center Groningen, the Netherlands
| |
Collapse
|